Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Hamilton, EP, and Blackwell, KL. "Safety of bevacizumab in patients with metastatic breast cancer." Oncology 80, no. 5-6 (2011): 314-325. (Review)

PMID
21778772
Full Text

Hamilton, EP, and Blackwell, KL. "Third-generation aromatase inhibitors: Differences between the agents and their role in reducing the risk of distant metastasis and improving survival." European Journal of Clinical and Medical Oncology 2, no. 4 (December 1, 2010).

Scholars@Duke

Spector, NL, and Blackwell, KL. "Reply to F. Bellati et al." Journal of Clinical Oncology 28, no. 21 (July 20, 2010). (Letter)

Full Text

Blackwell, KL, Burstein, HJ, Storniolo, AM, Rugo, H, Sledge, G, Koehler, M, Ellis, C, Casey, M, Vukelja, S, Bischoff, J, Baselga, J, and O'Shaughnessy, J. "Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28, no. 7 (March 2010): 1124-1130.

PMID
20124187
Full Text

Zagar, TM, Oleson, JR, Vujaskovic, Z, Dewhirst, MW, Craciunescu, OI, Blackwell, KL, Prosnitz, LR, and Jones, EL. "Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data." International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 26, no. 7 (January 2010): 612-617. (Review)

PMID
20849256
Full Text

Zagar, TM, Oleson, JR, Vujaskovic, Z, Dewhirst, MW, Craciunescu, OI, Blackwell, KL, Prosnitz, LR, and Jones, EL. "Hyperthermia for locally advanced breast cancer." Int J Hyperthermia 26, no. 7 (2010): 618-624. (Review)

PMID
20849257
Full Text

Vujaskovic, Z, Kim, DW, Jones, E, Lan, L, McCall, L, Dewhirst, MW, Craciunescu, O, Stauffer, P, Liotcheva, V, Betof, A, and Blackwell, K. "A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer." Int J Hyperthermia 26, no. 5 (2010): 514-521.

PMID
20377362
Full Text

Mouridsen, HT, Lønning, P, Beckmann, MW, Blackwell, K, Doughty, J, Gligorov, J, Llombart-Cussac, A, Robidoux, A, Thürlimann, B, and Gnant, M. "Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer." Expert Review of Anticancer Therapy 10, no. 11 (2010): 1825-1836.

PMID
20883112
Full Text

Russell, SD, Blackwell, KL, Lawrence, J, Jr, JEP, Roe, MT, Wood, F, Paton, V, Holmgren, E, and Mahaffey, KW. "Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials." Journal of Clinical Oncology 28, no. 21 (2010): 3416-3421.

PMID
20530275
Full Text

Spector, NL, and Blackwell, KL. "Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer." J Clin Oncol 27, no. 34 (December 1, 2009): 5838-5847. (Review)

PMID
19884552
Full Text

Pages